Harvard Business Review Names Allergan's David E. I. Pyott a Top CEO
10/15/2014
David E.I. Pyott, Chairman of the Board and Chief Executive Officer of Allergan, Inc., has been ranked the 4th best-performing CEO in the world by the Harvard Business Review (HBR). Mr. Pyott was selected for this honor out of a total of 832 current CEOs in 30 countries who qualified for consideration by HBR. The complete list, which has been published in HBR's November 2014 issue, ranks CEOs worldwide based upon performance over their entire tenure.
In compiling its list, HBR examined the track records of the CEOs of the S&P Global 1200 who assumed their role between 1995 and April 30, 2012. For each CEO, HBR looked at three quantitative metrics: industry-adjusted shareholder returns, country-adjusted shareholder returns, and increase in market capitalization over the CEO's tenure. HBR designed its methodology to make an objective determination of which global CEOs have had the greatest success delivering results over the long-term. Reputation and anecdote have no bearing on the outcome of the ranking.
Since becoming Allergan's CEO in January 1998, Mr. Pyott has delivered a country-adjusted shareholder return of 1,948% and an industry-adjusted shareholder return of 1,929%. Allergan's increase in market capitalization during this same period has exceeded $50 billion.
In compiling its list, HBR examined the track records of the CEOs of the S&P Global 1200 who assumed their role between 1995 and April 30, 2012. For each CEO, HBR looked at three quantitative metrics: industry-adjusted shareholder returns, country-adjusted shareholder returns, and increase in market capitalization over the CEO's tenure. HBR designed its methodology to make an objective determination of which global CEOs have had the greatest success delivering results over the long-term. Reputation and anecdote have no bearing on the outcome of the ranking.
Since becoming Allergan's CEO in January 1998, Mr. Pyott has delivered a country-adjusted shareholder return of 1,948% and an industry-adjusted shareholder return of 1,929%. Allergan's increase in market capitalization during this same period has exceeded $50 billion.